Brivanib | B1325

Brivanib is a potent, ATP-competitive inhibitor against human Flk-1 (VEGFR-2) and mouse Flk-1 with IC₅₀ of 25 nM and 89 nM, respectively. Brivanib also inhibits VEGFR-1 and FGFR-1 with IC₅₀ values of 0.38 and 0.148 μM. Brivanib displays antitumor activities in H3396 xenograft.

Brivanib is a potent, ATP-competitive inhibitor against human Flk-1 (VEGFR-2) and mouse Flk-1 with IC₅₀ of 25 nM and 89 nM, respectively. Brivanib also inhibits VEGFR-1 and FGFR-1 with IC₅₀ values of 0.38 and 0.148 μM. Brivanib displays antitumor activities in H3396 xenograft.

B1325 | Brivanib DataSheet

Alternate Name/Synonyms: (R)-1-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)propan-2-ol; BMS-540215

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 649735-46-6

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₉H₁₉FN₄O₃

Molecular Weight: 370.38

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (>30 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent, ATP-competitive inhibitor against human Flk-1 (VEGFR-2) and mouse Flk-1

MDL Number: N/A

PubChem CID: 11234052

SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C

InChi: InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1

InChi Key: WCWUXEGQKLTGDX-LLVKDONJSA-N